HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA

The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.

Europe Approvals

Ipsen Upbeat Despite Palovarotene Pain

The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.

Sales & Earnings Rare Diseases

Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine

Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.

Research & Development Vaccines

Ligand Buys Into Ongoing Partnerships With Icagen Deal

Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform capabilities in acquiring Icagen’s North Carolina operations.

Deals Business Strategies
See All

Company Information

UsernamePublicRestriction

Register